All IndicationsPhase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 2
SARS-CoV-2 Infection
1
Companies
8
Drug Programs
7
Phase 3
0
Upcoming PDUFAs
Competitors
BNTX
BioNTech SE
BNT162b2
BNTX
BioNTech SE
BNT162b2 (Omi XBB.1.5)
BNTX
BioNTech SE
BNT162b1
BNTX
BioNTech SE
BNT162b2 OMI
BNTX
BioNTech SE
BNT162b5 Bivalent (WT/OMI BA.2)
BNTX
BioNTech SE
BNT162b2.B.1.351
BNTX
BioNTech SE
Seasonal Inactivated Influenza Vaccine
BNTX
BioNTech SE
Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| BNTX BioNTech SE | BNT162b2 | Phase 3 | — | — | — |
| BNTX BioNTech SE | BNT162b2 (Omi XBB.1.5) | Phase 3 | — | — | — |
| BNTX BioNTech SE | BNT162b1 | Phase 3 | — | — | — |
| BNTX BioNTech SE | BNT162b2 OMI | Phase 3 | — | — | — |
| BNTX BioNTech SE | BNT162b5 Bivalent (WT/OMI BA.2) | Phase 3 | — | — | — |
| BNTX BioNTech SE | BNT162b2.B.1.351 | Phase 3 | — | — | — |
| BNTX BioNTech SE | Seasonal Inactivated Influenza Vaccine | Phase 3 | — | — | — |
| BNTX BioNTech SE | Multivalent BNT162b2 (B.1.1.7 + B.1.617.2) | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
7
Phase 2
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.